[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-337041-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-337041-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","targeting-drug-resistance-in-breast-cancer-the-potential-of-mirna-and-nanotechnology-driven-delivery-systems","Targeting drug resistance in breast cancer - the potential of miRNA and nanotechnology-driven delivery systems","","Breast cancer remains a leading cause of cancer mortality in women worldwide, and drug resistance continues to limit the effectiveness of therapies. Key resistance mechanisms include altered drug uptake, enhanced DNA repair, and dysregulated apoptosis, with frequent resistance observed in HER2-positive and triple-negative subtypes. This review summarizes how microRNAs can regulate drug-resistance pathways and how nano-drug delivery systems improve microRNA stability, targeting, and cellular uptake to enhance clinical efficacy.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/targeting-drug-resistance-in-breast-cancer-the-potential-of-mirna-and-nanotechnology-driven-delivery-systems/337041/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/targeting-drug-resistance-in-breast-cancer-the-potential-of-mirna-and-nanotechnology-driven-delivery-systems/337041.png","ImageObject",300,407,{"name":42,"@type":43},"Seraphina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-09","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What makes drug resistance a major challenge in breast cancer treatment?","Question",{"text":63,"@type":64},"Drug resistance limits therapy effectiveness by involving mechanisms such as altered drug uptake, enhanced DNA repair, and dysregulated apoptosis pathways.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How can microRNAs help overcome drug resistance in breast cancer?",{"text":68,"@type":64},"MicroRNAs can regulate cellular and molecular pathways that confer drug resistance, offering a route to improve treatment response.",{"name":70,"@type":61,"acceptedAnswer":71},"Why are nanotechnology-driven delivery systems important for microRNA therapies?",{"text":72,"@type":64},"They improve microRNA stability, enable targeting of specific cells, and enhance cellular uptake, increasing the likelihood of therapeutic impact.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},337041,1790186708,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962075114101,"https://ap-avatar.wpscdn.com/avatar/e000253a75eb197efd?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780044092746381165","Nanoscale Advances  \nREVIEW  \nCite this: DOI: 10 .1039/d4na00660g  \nReceived 9th August 2024  \nAccepted 11th November 2024 DOI: 10.1039/d4na00660g[rsc.li/nanoscale-advances](rsc.li/nanoscale-advances)  \nTargeting drug resistance in breast cancer: the potential of miRNA and nanotechnology-driven delivery systems  \nAditi Verma,  Krunal Patel  and Ashutosh Kumar  *  \nBreast cancer is the second leading cause of cancer-related deaths in females worldwide. Despite signiﬁcant advancements in treatment, drug resistance remains a major challenge, limiting theeﬀectiveness of therapies and leading to dismal outcomes. Approximately 50% of HER2+ breast cancer patients develop resistance to trastuzumab, and patients with triple-negative breast cancer often experience resistance to ﬁrst-line therapies. The drug resistance mechanisms involve altered drug uptake, enhanced DNA repair, and dysregulated apoptosis pathways. MicroRNAs are essential in regulating cellular processes involved in both homeostasis and disease. Recent data suggest that microRNAs can overcome drug resistance by regulating the pathways that confer drug resistance. Combining diﬀerent conventional anticancer agents with microRNA therapies holds promise for enhancing treatment eﬀectiveness against drug resistant breast cancer. Advancements in nano-drug delivery systems have facilitated the eﬀective delivery of microRNAs by improving their stability, targeting speciﬁc cells, and enhancing cellular uptake. This review elucidates the recent advancements in microRNA-based therapies, their eﬀects on gene expression, and their clinical eﬃcacy in overcoming drug resistance in breast cancer.  \n1. Introduction  \nBreast cancer remains a signi􀀁cant global health challenge, with over 3.13 million new cases and an estimated 42 780 deaths in the U.S. alone in 2024 .1 Breast cancer is classi􀀁ed into four molecular subtypes: luminal A, luminal B, HER2-positive, and triple-negative, based on receptor expression. Despite decades of advances, overcoming drug resistance remains the top hurdle in reducing breast cancer's signi􀀁cant mortality rate in women.2 Chemoresistance refers to the phenomenon of drug resistance in cancer cells, which can arise due to mechanisms such as drug eﬄux, alteration of drug targets, DNA repair, loss of cell death, epithelial to mesenchymal transition (EMT) or epigenetic changes.3 The mechanisms of resistance can be broadly classi-􀀁ed into intrinsic and acquired categories. Intrinsic resistance in breast cancer involves various pathways and alterations, contributing to treatment insensitivity, hindrance of antitumor immunity, and promotion of cancer progression.4  \nThe major factors of intrinsic resistance include (1) inherited genetic alterations in tumor cells leading to unresponsiveness to both traditional chemotherapy and targeted therapies, (2) tumor heterogeneity, which encompasses subsets of cancer stem cells capable of regenerating new tumor cells and causing  \nBiological and Life Sciences, School of Arts & Sciences, Ahmedabad University, Central Campus, Navrangpura, Ahmedabad 380009, Gujarat, India. E-mail: ashutosh. [kumar@ahduni.edu.in](kumar@ahduni.edu.in)  \nrecurrence, and (3) pharmacokinetic factors such as absorption, distribution, metabolism, and excretion (ADME), as well aspharmacogenetic patterns, which can limit the drug's eﬃcacy in reaching and acting upon tumor cells.5 Acquired resistance in cancer refers to the development of resistance to treatment overtime, driven by genetic or environmental factors, leading to reduced drug eﬃcacy, therapy failure, and tumor progression. This resistance can arise from (1) activation of secondary protooncogenes, resulting in the emergence of a new driving gene,(2) alterations in the tumor microenvironment following treatment, and (3) modi􀀁cations in drug targets due to changes in gene expression or mutation. Notably, CDK4/6 inhibition demonstrates early adaptation and acquired resistance in estrogen receptor-po","cbCaif8soOOXnAv5","https://ap.wps.com/l/cbCaif8soOOXnAv5","pdf",1109917,17,"English","# Introduction\n## Drug resistance mechanisms and classifications\n## Multidrug resistance and DRAMPs\n# Drug resistance in breast cancer\n## Triple-negative resistance and common therapies","[{\"question\":\"What makes drug resistance a major challenge in breast cancer treatment?\",\"answer\":\"Drug resistance limits therapy effectiveness by involving mechanisms such as altered drug uptake, enhanced DNA repair, and dysregulated apoptosis pathways.\"},{\"question\":\"How can microRNAs help overcome drug resistance in breast cancer?\",\"answer\":\"MicroRNAs can regulate cellular and molecular pathways that confer drug resistance, offering a route to improve treatment response.\"},{\"question\":\"Why are nanotechnology-driven delivery systems important for microRNA therapies?\",\"answer\":\"They improve microRNA stability, enable targeting of specific cells, and enhance cellular uptake, increasing the likelihood of therapeutic impact.\"}]","Targeting drug resistance in breast cancer - the potential of miRNA and nanotechnology-driven delivery systems | PDF",1790017485,43,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/11998d5fb6a8d24c6e90b755ed22b60d.webp",983,1287,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5c3d12ecb90e787286bfcd5d02658980.webp",982,1286,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4f5eef40f8b2d50e5155a24d6c5caab9.webp",981,1284,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/04dcac04a11bbd8216b4d86e4a6cc546.webp",980,1283]